
ImmunoBrain Checkpoint Awarded $5 Million US NIA Grant for Phase 1b Alzheimer’s Disease
ImmunoBrain Checkpoint Awarded $5 Million US NIA Grant for Phase 1b Alzheimer’s Disease Proof-of-Mechanism Study of Anti-PD-L1 IBC-Ab002...
ImmunoBrain Checkpoint Awarded $5 Million US NIA Grant for Phase 1b Alzheimer’s Disease
Advaxis and Biosight Announce Entry into Definitive Merger Agreement
LogicBio Announces First Patient Dosed in Groundbreaking Phase 1/2 SUNRISE Clinical Trial
Chemomab Announces Enrollment of First Patient in Phase 2a Study of CM-101 in NASH
LogicBio Therapeutics Announces Research Collaboration with Daiichi Sankyo